Magazine Article | June 1, 2022

Companies To Watch: CinCor Pharma

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

CinCor Pharma is developing a “pipeline in a product” for the long-quiet area of hypertension, specifically the kind that existing treatments fail to control. The first three programs are in its broader target area of cardio-renal disease, testing a single drug. Coded CIN-107, the once-daily oral drug is a “highly specific” aldosterone synthase inhibitor (ASI) now in three Phase 2 programs, one focused on treatment-resistant hypertension (rHTN), another on uncontrolled hypertension (uHTN), and the third on primary aldosteronism (PA).

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: